KOBAYASHI PHARMACEUTICAL CO., LTD. a drug manufacturer. The Company operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.

Employees

3,615

Sector

Personal Products

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-07-10	5,214.00 ¥	-0.55%	281,800
25-07-09	5,243.00 ¥	+0.17%	239,700
25-07-08	5,234.00 ¥	-0.53%	199,000
25-07-07	5,262.00 ¥	0.00%	156,500
25-07-04	5,262.00 ¥	-1.09%	147,900

Delayed Quote Japan Exchange, July 10, 2025 at 02:30 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

BBB

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5,214.00JPY

Average target price

5,567.50JPY

Spread / Average Target

+6.78%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-07-10 EDT			5-day change	1st Jan Change
5,214.00 ^JPY	-0.55%		-2.25%	-16.31%

06-12	Kobayashi Pharmaceutical Co., Ltd. Require Kazumasa Kobayashi and Akihiro Kobayashi to Resign from Their Roles as Special Advisor and Director in Charge of Compensation, Respectively	CI
04-25	Kobayashi Pharmaceutical Co Ltd - Received Notice Of Lawsuit Filing From Shareholder Oasis Japan Strategic Fund	RE

Capitalization	388B 2.65B 2.26B 2.11B 1.95B 3.62B 227B 4.03B 25.23B 9.64B 106B 9.93B 9.72B	P/E ratio 2025 *	31.8x	P/E ratio 2026 *	26.3x
Enterprise value	330B 2.25B 1.93B 1.79B 1.66B 3.08B 193B 3.43B 21.45B 8.19B 90.15B 8.44B 8.27B	EV / Sales 2025 *	1.93x	EV / Sales 2026 *	1.8x
Free-Float	60.58%	Yield 2025 *	1.99%	Yield 2026 *	2.01%

Kobayashi Pharmaceutical Co., Ltd. Require Kazumasa Kobayashi and Akihiro Kobayashi to Resign from Their Roles as Special Advisor and Director in Charge of Compensation, Respectively	06-12	CI
Kobayashi Pharmaceutical Co Ltd - Received Notice Of Lawsuit Filing From Shareholder Oasis Japan Strategic Fund	04-25	RE
Oasis Management - Filed Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors	04-06	RE
Oasis Files Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors	04-06	CI
Kobayashi Pharmaceutical Co. Announces CEO Changes	03-28	CI
Kobayashi Pharmaceutical Co. Announces Executive Changes	03-28	CI
Declaration of Voting Results by Kobayashi Pharmaceutical	03-28	CI
Oasis Management Company Issues Recommendations to Shareholders of Kobayashi Pharmaceutical	03-11	CI
Oasis: Urges Shareholders To Vote Against Appointment Of Akihiro Kobayashi, Others As Directors At Kobayashi Pharma AGM	03-10	RE
Oasis Management Urges Shareholders to Vote Against Kobayashi Pharmaceutical?s Directors	03-10	CI
Independent Proxy Advisory Firms Supports Oasis Management Proposals	02-17	CI
Glass Lewis ESG Controversy Alert: Kobayashi Pharmaceutical	02-17	MT
Satoshi Yamane Will Step Down as Executive Officer of Kobayashi Pharma	01-21	CI

Jefferies Adjusts Kobayashi Pharmaceutical's Price Target to 4,900 Yen From 4,800 Yen, Keeps at Underperform	11-01	MT
UBS Adjusts Kobayashi Pharmaceutical's Price Target to 12,600 Yen From 13,100 Yen, Keeps at Buy	22-03-03	MT

Kobayashi Pharmaceutical Co., Ltd. Stock

Equities

4967

JP3301100008

Personal Products

Valuation: Kobayashi Pharmaceutical Co., Ltd.

Chart: Kobayashi Pharmaceutical Co., Ltd.

Latest news: Kobayashi Pharmaceutical Co., Ltd.

Analysts' recommendations: Kobayashi Pharmaceutical Co., Ltd.

Press Releases: Kobayashi Pharmaceutical Co., Ltd.

News in other languages: Kobayashi Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Kobayashi Pharmaceutical Co., Ltd.

ETFs: Kobayashi Pharmaceutical Co., Ltd.

Other Personal Products

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Voting Cards Reveal that Over 50% of Shareholders Excluding the Founding Family and Related Parties Voted For Oasis’s EGM Proposals and Against Mr. Akihiro Kobayashi’s Renomination at the AGM	06-11	BU
Kobayashi Pharmaceutical : FY2025（January 1, 2025 - December 31, 2025）1Q Financial Statement	05-08	PU
Kobayashi Pharmaceutical : Financial Overview for First Quarter of Fiscal 2025(Fiscal Year Ending December 31, 2025)	05-08	PU
Oasis Files Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors	04-06	BU
Oasis Urges All Shareholders to Vote AGAINST the Appointment of Mr. Akihiro Kobayashi, Mr. Katae, Mr. Ohta and Mr. Takahashi as Directors at the Kobayashi Pharma AGM	03-10	BU

Razzia bei japanischem Pharma-Konzern nach Todesfällen	24-03-31
Scandale aux compléments alimentaires au Japon: deux nouveaux décès suspects	24-03-28
Bourses asiatiques: Tokyo soutenue par la chute du yen	24-03-27
Tokyo en hausse en matinée	24-03-26

1 day	-0.55%
1 week	-2.25%
Current month	-3.32%
1 month	-6.00%
3 months	+0.87%
6 months	-11.81%
Current year	-16.31%

1 week	5,194	5,319
1 month	5,194	5,678
Current year	4,850	6,220
1 year	4,850	6,350
3 years	4,700	9,410
5 years	4,700	13,120
10 years	4,080	13,120

Manager	Title	Age	Since
Akihiro Kobayashi PSD	President	54	2013-05-31
Noriaki Hirao IRC	Investor Relations Contact	-	-
Kenji Kohori SAM	Sales & Marketing	70	-

Director	Title	Age	Since
Akihiro Kobayashi BRD	Director/Board Member	54	2004-05-31
Kunio Ito BRD	Director/Board Member	73	2013-05-31
Kaori Sasaki BRD	Director/Board Member	66	2016-05-31

Name	Weight	AuM	1st Jan change
NOMURA NEXT FUNDS TOPIX-17 RAW MATERIALS & CHEMICALS ETF - JPY	1.19%	7 M€	-3.50%	-
NEXT FUNDS MSCI JAPAN COUNTRY ESG LEADERS INDEX EXCHANGE TRADED FUND - JPY	0.21%	14 M€	-1.44%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
KOBAYASHI PHARMACEUTICAL CO., LTD.	-0.55%	-2.25%	-4.77%	-40.95%	2.66B
PROCTER & GAMBLE COMPANY	+0.84%	-0.91%	-4.45%	+9.13%	369B
UNILEVER PLC	+1.87%	+0.89%	+2.72%	+17.55%	150B
COLGATE-PALMOLIVE COMPANY	-0.21%	-1.36%	-6.03%	+16.29%	74.22B
HINDUSTAN UNILEVER LIMITED	-0.62%	+4.39%	-7.02%	-3.54%	66.42B
KENVUE INC.	+1.13%	-0.45%	+18.39%	-	39.86B
ESTEE LAUDER	+6.19%	+3.64%	-10.04%	-62.56%	31.16B
BEIERSDORF	+1.46%	+2.54%	-19.87%	+13.02%	28.23B
ESSITY AB	+1.33%	+0.11%	-3.91%	-1.87%	19.11B
GODREJ CONSUMER PRODUCTS LIMITED	-0.55%	+9.54%	-8.88%	+51.33%	15.44B
Average	+1.08%	+1.01%	-4.39%	-0.18%	79.68B
Weighted average by Cap.	+1.03%	-0.49%	-3.16%	+7.99%

	2025 *	2026 *
Net sales	170B 1.16B 996M 928M 858M 1.59B 99.82B 1.77B 11.1B 4.24B 46.64B 4.37B 4.28B	179B 1.22B 1.05B 975M 902M 1.67B 105B 1.86B 11.66B 4.45B 49B 4.59B 4.49B
Net income	12.18B 83.19M 71.18M 66.32M 61.33M 114M 7.13B 127M 793M 303M 3.33B 312M 306M	14.75B 101M 86.2M 80.32M 74.28M 138M 8.64B 153M 960M 367M 4.04B 378M 370M
Net Debt	-58.1B -397M -339M -316M -293M -543M -34.02B -605M -3.78B -1.44B -15.9B -1.49B -1.46B	-65.07B -444M -380M -354M -328M -608M -38.1B -677M -4.24B -1.62B -17.8B -1.67B -1.63B